NOTE: Many features on this website require Javascript and cookies. You can enable both via your browser's preference settings.
NEJM - 21/05/2007 16:58:22
Background Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. Methods We conducted searches of ...
Sign in or register to comment on this story